Array Biopharma (ARRY) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2019
May 7, 2019 8:02 AM EDTBOULDER, Colo., May 7, 2019 /PRNewswire/ --Â Array BioPharma Inc. (Nasdaq: ARRY) today reported results for its third quarter of fiscal 2019 and provided an update on the progress of its key commercial products and clinical development programs.
"U.S. demand for BRAFTOVI + MEKTOVI for patients with BRAF-mutant metastatic melanoma continues to be strong with over $35 million in net product sales during the third commercial quarter," said Ron Squarer, Chief Executive Officer. "We are also pleased the combination of BRAFTOVI, MEKTOVI and cetuximab or panitumumab was recommended by NCCN guidelines as a... More
